BOSTON--(BUSINESS WIRE)--Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular ...

BOSTON--(BUSINESS WIRE)--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added ...

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that its Plaque-IQ ...

Elucid's new Lesion Inspection Tool for coronary and carotid plaque analysis in its Plaque-IQ software suite provides physicians the ability to interrogate lesion-specific composition and plaque ...

BOSTON, December 03, 2025--(BUSINESS WIRE)--Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & ...

Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ(TM) ...

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques Elucid CEO Kelly Huang, PhD, will ...

New functionality puts the power of lesion-specific plaque analysis directly into the physician’s hands, giving deeper insight into coronary and carotid artery disease Elucid announced today the ...